Opna Bio's Zavabresib Earns FDA Orphan Status for Myelofibrosis

SOUTH SAN FRANCISCO, CA – January 21, 2026 – Opna Bio, a clinical-stage biopharmaceutical company, has received a significant regulatory endorsement from the U.S. Food and Drug Administration (FDA) for its investigational cancer therapy, zavabresib. The drug, a small molecule inhibitor also known as OPN-2853, was granted Orphan Drug Designation for the treatment of myelofibrosis, a rare and aggressive blood cancer. This milestone highlights a critical unmet need for new treatments and provides a clearer, incentivized path toward potential approval for a therapy showing promise in early clinical trials.

Myelofibrosis affects approximately 25,000 people in the United States, making it a rare disease but one with devastating consequences for those diagnosed. The designation for zavabresib, which also recently received its approved generic name from the International Nonproprietary Names program, signals regulatory recognition of its potential to provide a meaningful benefit to this patient population.

A New Lifeline for Patients with a Devastating Disease

Myelofibrosis is a type of chronic leukemia characterized by the progressive buildup of scar tissue, or fibrosis, in the bone marrow. This scarring disrupts the body's ability to produce healthy blood cells, leading to severe anemia, profound fatigue, weakness, and an enlarged spleen (splenomegaly) as the organ tries to compensate for the failing bone marrow. Patients often suffer from debilitating constitutional symptoms, including night sweats, fever, and bone pain, which severely impact their quality of life.

The current standard of care for many intermediate and high-risk patients revolves around Janus kinase (JAK) inhibitors, most notably ruxolitinib. These drugs have been transformative, effectively reducing spleen size and alleviating symptoms for many. However, a significant portion of patients either have a suboptimal initial response or become resistant to the therapy over time, leaving them with few effective options as the disease progresses.

It is this critical treatment gap that Opna Bio aims to fill with zavabresib. The therapy is being developed not as a replacement for the current standard of care, but as an add-on for myelofibrosis patients who are no longer benefiting from ruxolitinib alone. This strategy targets a population with a particularly poor prognosis and an urgent need for novel therapeutic approaches.

Promising Early Results from Combination Therapy

Zavabresib belongs to a class of drugs known as bromodomain and extra-terminal motif (BET) inhibitors. These molecules work at an epigenetic level, targeting proteins that regulate the expression of key genes involved in cancer cell proliferation and inflammation. By inhibiting BET proteins, zavabresib can disrupt the abnormal genetic signaling that drives myelofibrosis.

The scientific rationale for its use is bolstered by a combination strategy. Preclinical studies have shown that pairing a BET inhibitor with a JAK inhibitor can attack the disease from two different angles, potentially leading to deeper and more durable responses than either agent could achieve alone. This hypothesis is being tested in the ongoing Phase 1 PROMise study, an investigator-sponsored trial led by Professor Adam Mead at the University of Oxford in collaboration with Cancer Research UK.

Early results from this study have been highly encouraging. Data presented at the American Society of Hematology (ASH) annual conference in December 2025 showed that the combination of zavabresib and ruxolitinib yielded impressive results. Among 26 evaluable patients with advanced myelofibrosis who had a suboptimal response to ruxolitinib, 16 patients (over 60%) achieved a 50% or greater reduction in spleen length from baseline. The combination was also reported to be well-tolerated, a critical factor for patients who are often already frail.

“Receiving Orphan Drug Designation for zavabresib in myelofibrosis is a significant regulatory milestone for Opna Bio and highlights the urgent need for new and effective treatment options for patients with this disease,” said Reinaldo Diaz, chief executive officer of Opna Bio, in a statement. “Our investigator-sponsored clinical trial with zavabresib and ruxolitinib has shown impressive results to date, including durable spleen reduction in patients with advanced myelofibrosis. We believe that selective BET inhibition alongside JAK inhibition offers a promising new therapeutic approach for patients with myelofibrosis.”

The Strategic Value of Orphan Drug Designation

For a clinical-stage company like Opna Bio, receiving Orphan Drug Designation is more than a procedural step; it is a transformative strategic victory. The designation is granted by the FDA to drugs intended for rare diseases affecting fewer than 200,000 people in the U.S. It is designed to de-risk and incentivize the development of therapies that might otherwise be considered commercially unviable due to small patient populations.

The benefits are substantial. Upon potential FDA approval, zavabresib would be eligible for seven years of market exclusivity for the treatment of myelofibrosis, protecting it from generic competition. Furthermore, the designation provides Opna Bio with significant financial advantages, including tax credits for qualified clinical trial costs and a waiver of the Prescription Drug User Fee Act (PDUFA) fee, which can save the company millions of dollars when submitting a New Drug Application.

This regulatory support provides crucial momentum, making the program more attractive to investors and potential partners. It also facilitates closer collaboration with the FDA throughout the development process, potentially streamlining the path to market. This milestone validates the company's scientific approach and strengthens its position as it moves into more advanced clinical studies.

Navigating a Competitive but Growing Market

While the need is great, Opna Bio is entering a dynamic and increasingly competitive therapeutic landscape. The global myelofibrosis market is projected to grow substantially, reaching over $5.6 billion by 2034, attracting numerous developers. The field is not only dominated by established JAK inhibitors but also features a robust pipeline of novel agents.

Notably, zavabresib is not the only BET inhibitor vying for a place in the treatment paradigm. Pelabresib, developed by MorphoSys (now part of Novartis), is also being tested in combination with ruxolitinib and has shown strong results in a Phase 3 trial. The advancement of multiple drugs in this class validates the therapeutic target but also sets the stage for a competitive race to market.

Opna Bio's strategy appears focused on carving out a distinct and critical niche: patients who have already been treated with and are no longer adequately responding to the current standard of care. Success in this refractory setting could provide a clear path to initial approval and market entry. The company's broader pipeline, which includes a dual EP300/CBP inhibitor for multiple myeloma (OPN-6602) that also received Orphan Drug Designation, demonstrates a diversified approach to tackling complex cancers.

With positive early data, a key regulatory designation in hand, and what the company describes as encouraging recent meetings with the FDA, Opna Bio is positioned to advance zavabresib into further clinical studies. The journey is long, but for myelofibrosis patients awaiting better options, this progress represents a tangible step forward and a renewed sense of hope.